# The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients

> **NCT04728516** · PHASE4 · RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 2600 (estimated)

## Conditions studied

- Acute Coronary Syndrome
- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Vonoprazan-based dual eradication therapy for two weeks
- **DRUG:** amoxicillin
- **DRUG:** Pantoprazole

## Key facts

- **NCT ID:** NCT04728516
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-12
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 2600 (ESTIMATED)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04728516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04728516, "The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04728516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*